SEARCH

SEARCH BY CITATION

References

  • 1
    Mackay IR, Rosen FS, Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med 2001;345:13315.
  • 2
    Zinkernagel RM, Lamarre A, Ciurea A et al. Neutralizing antiviral antibody responses. Adv Immunol 2001;79:153.
  • 3
    Kwong PD, Doyle ML, Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420:67882.
  • 4
    Wei X, Decker JM, Liu H et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002;46:1896905.
  • 5
    Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 2003;422:30712.
  • 6
    Donners H, Willems B, Beirnaert E, Colebunders R, Davis D, van der Groen G. Cross-neutralizing antibodies against primary isolates in African women infected with HIV-1. AIDS 2002;16:501.
  • 7
    Nyambi PN, Nkengasong J, Lewi P et al. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol 1996;70:623543.
  • 8
    Vujcic LK, Quinnan Jr GV. Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res Hum Retroviruses 1995;11:7837.
  • 9
    Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004;5:2336.
  • 10
    Wu X, Yang ZY, Li Y et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329:85661.
  • 11
    Walker LM, Phogat SK, Chan-Hui PY et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:2859.
  • 12
    Braibant M, Brunet S, Costagliola D et al. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity. AIDS 2006;20:192330.
  • 13
    Moog C, Fleury H, Pellegrin I, Kirn A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997;71:373441.
  • 14
    Pilgrim AK, Pantaleo G, Cohen OJ et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997;176:92432.
  • 15
    Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci 2003;100:41449.
  • 16
    Wang L. Overview of the HIV/AIDS epidemic, scientific research and government responses in China. AIDS 2007;21:S3.
  • 17
    Lu L, Jia M, Ma Y et al. The changing face of HIV in China. Nature 2008;455:60911.
  • 18
    Li M, Gao F, Mascola JR et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005;79:1010825.
  • 19
    Beddows S, Schülke N, Kirschner M et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005;79:881227.
  • 20
    Shang H, Han X, Shi X et al. Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J Biol Chem 2011;286:1453141.
  • 21
    Nelson JD, Brunel FM, Jensen R et al. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 2007;81:403343.
  • 22
    Zwick MB, Labrijn AF, Wang M et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75:10892905.
  • 23
    Li Y, Svehla K, Louder MK et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009;83:104559.
  • 24
    Shen X, Parks RJ, Montefiori DC et al. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009;83:361725.
  • 25
    Sather DN, Armann J, Ching LK et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009;83:75769.
  • 26
    Thali M, Furman C, Ho D et al. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 1992;66:563541.
  • 27
    Wyatt R, Kwong PD, Desjardins E et al. The antigenic structure of the HIVgp120 envelope glycoprotein. Nature (Lond) 1998;393:70511.
  • 28
    Thali M, Olshevsky U, Furman C, Gabuzda D, Li J, Sodroski J. Effects of changes in gp120-CD4 binding affinity on human immunodeficiency virus type 1 envelope glycoprotein function and soluble CD4 sensitivity. J Virol 1991;65:500712.
  • 29
    Li Y, Migueles SA, Welcher B et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007;13:10324.
  • 30
    Thali M, Olshevsky U, Furman C, Gabuzda D, Posner M, Sodroski J. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J Virol 1991;65:618893.
  • 31
    Scanlan CN, Pantophlet R, Wormald MR et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of α1[RIGHTWARDS ARROW]2 mannose residues on the outer face of gp120. J Virol 2002;76:730621.
  • 32
    Scanlan CN, Ritchie GE, Baruah K et al. Inhibition of mammalian glycan biosynthesis produces non-self antigens for a broadly neutralising, HIV-1 specific antibody. J Mol Biol 2007;372:1622.
  • 33
    Doores KJ, Burton DR. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol 2010;84:1051021.
  • 34
    Zhang M, Jiao Y, Wang S et al. Serum Neutralizing Activities from a Beijing Homosexual Male Cohort Infected with Different Subtypes of HIV-1 in China. PLoS ONE 2012;7:e47548.
  • 35
    Haynes BF, Fleming J, Clair EWS et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005;308:19068.
  • 36
    Walker LM, Simek MD, Priddy F et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010;6:e1001028.
  • 37
    Binley JM, Lybarger EA, Crooks ET et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008;82:1165168.
  • 38
    Corti D, Langedijk JPM, Hinz A et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010;5:e8805.
  • 39
    Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004;78:520515.
  • 40
    Gorny MK, Moore JP, Conley AJ et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68:8312.
  • 41
    Pinter A, Honnen W, Kayman S, Trochev O, Wu Z. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine 1998;16:180311.